Teladoc Health, Inc.
TDOC · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.16 | -0.00 | 0.68 |
| FCF Yield | 18.25% | 5.54% | 0.43% | 0.90% |
| EV / EBITDA | 57.90 | 90.88 | -593.55 | -470.59 |
| Quality | ||||
| ROIC | -32.80% | -6.26% | -344.75% | -1.70% |
| Gross Margin | 70.76% | 70.80% | 69.09% | 68.01% |
| Cash Conversion Ratio | -0.29 | -1.59 | -0.01 | -0.45 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.20% | 8.58% | 30.06% | 54.30% |
| Free Cash Flow Growth | 46.07% | 1,071.79% | -87.29% | 263.48% |
| Safety | ||||
| Net Debt / EBITDA | 9.02 | 10.74 | -86.92 | -11.90 |
| Interest Coverage | -42.89 | -11.15 | -622.18 | -3.27 |
| Efficiency | ||||
| Inventory Turnover | 19.70 | 25.75 | 13.20 | 8.90 |
| Cash Conversion Cycle | 34.25 | 25.48 | 39.98 | 48.63 |